Ikesue, H., Doi, K., Morimoto, M., Hirabatake, M., Muroi, N., Yamamoto, S., . . . Hashida, T. (2021). Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. Cancer Chemother Pharmacol.

Ikesue, Hiroaki, Kohei Doi, Mayu Morimoto, Masaki Hirabatake, Nobuyuki Muroi, Shinsuke Yamamoto, Toshihiko Takenobu, and Tohru Hashida. "Switching From Zoledronic Acid to Denosumab Increases the Risk for Developing Medication-related Osteonecrosis of the Jaw in Patients With Bone Metastases." Cancer Chemother Pharmacol 2021.

Ikesue, Hiroaki, et al. "Switching From Zoledronic Acid to Denosumab Increases the Risk for Developing Medication-related Osteonecrosis of the Jaw in Patients With Bone Metastases." Cancer Chemother Pharmacol 2021.